Assessment of the effects of telmisalthan and olmethaltan on inflammation and oxidative stress in patients on maintenance hemodialysis
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease stage5d
- Registration Number
- JPRN-UMIN000002413
- Lead Sponsor
- Ebara Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who has past history of adverse effect of taking another ARB 2) Pregnancy 3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome 4) Hemodialysis treatment for less than six months 5) Judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is the impact of termisartan and olmesartan on blood pressure at 4, 12 and 24 months after administration of the ARB case compared with at baseline.
- Secondary Outcome Measures
Name Time Method the secondary outcome is the impact of termisartan and olmesartan on inflammatory and oxidative stress markers (hsCRP, IL-6, IL-10. TNF, pentosidine, CML, PTX3, MPO, radical)at four and twelve months after administration of the ARB case compared with at baseline